Xavier Castellsagué

Post Hoc Analysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA

Frank Struyf, Brigitte Colau, Cosette M Wheeler, 2014, Clinical and Vaccine Immunology.

Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches

Xavier Castellsagué, X. Castellsagué, R. Weller, 2017, Dermatology and Therapy.

Using HPV prevalence to predict cervical cancer incidence

Mireia Diaz, Xavier Castellsagué, S. Sanjosé, 2013, International journal of cancer.

Using Prior Information from the Medical Literature in GWAS of Oral Cancer Identifies Novel Susceptibility Variant on Chromosome 4 - the AdAPT Method

Angus Roberts, Jon Wakefield, Hamish Cunningham, 2012, PloS one.

Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: The CLEOPATRE study

Laurence Serradell, Xavier Castellsagué, F. X. Bosch, 2012, Journal of medical virology.

Against which human papillomavirus types shall we vaccinate and screen? the international perspective

Xavier Castellsagué, N. Muñoz, S. de Sanjosé, 2004, International journal of cancer.

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

Xavier Castellsagué, Rosanna W Peeling, Silvia de Sanjosé, 2006, Journal of the National Cancer Institute.

Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-Analysis

Beibei Lu, Xavier Castellsagué, A. Giuliano, 2011, BMC infectious diseases.

Chapter 1: HPV in the etiology of human cancer.

Xavier Castellsagué, N. Muñoz, X. Castellsagué, 2006, Vaccine.